Watching alerts...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TenKay - I have a bold feeling those holding this right now are going to make out big. I understand your points, but sometimes technical details don't matter. It will fall into place.
Do we close lower today ;)
He's laughing at everyone on this board.
I like your view point.
It's in the scope... fingers ready.
Going to be hard to get those. Maybe one last quick chance but I think this run is soon. Glad to be in early.
$SWISF Preparing for NASDAQ Listing
(CSE: SKUR / OTCQX: SWISF / FRA: GDTO)
BUY
Current Price: C$0.09
Fair Value: C$0.83
Risk*: 4
Sector/Industry: Technology/Software
Q3 revenue was up 160% YoY, and 4% QoQ, beating our estimate by 3%.
Subscriber-count increased from 4k in September, to 5.1k currently; we are raising our year-end estimate from 5k to 5.25k.
Per our previous update in September, the company is in the process of shifting its marketing strategy by using more resellers and distributors, and in-house SEO marketing, instead of social media influencers. Management expects these initiatives to be more effective and cheaper. We are unable to comment on the effectiveness of these new initiatives until we see some preliminary results. For conservatism, we are lowering our near-term and long-term subscriber-count and revenue estimates.
Customer Acquisition Costs (CAC) remained well above $1,000 in Q3. Sekur expects to lower its CAC to $200-$250 in 2023, and to <$100 by 2024, vs subscription revenue of $150/year/user. We believe these cost reductions are achievable, if the company is able to ramp up its subscriber-base.
In 2023, the company is planning to launch new solutions/services, including VPN, encrypted calls, and video conferencing. These solutions can be bundled with existing solutions, or offered as stand-alone services.
2023 marketing will primarily target small businesses operating in the U.S. (approximately 32M. We continue to believe that businesses operating with sensitive and confidential information (such as medical, financial, and real estate) are ideal targets for Sekur.
Management is following through with their plan to up list shares to the NASDAQ; expected in 2023.
We expect tech stocks to be under pressure in the near-term, amid slower GDP growth, and as the Fed is expected to continue raising rates. That said, we are expecting the Fed to turn less hawkish by early next year, which should trigger a rally in tech stocks.
Sekur Private Data Ltd. - Preparing for NASDAQ Listing
(CSE: SKUR / OTCQX: SWISF / FRA: GDTO)
BUY
Current Price: C$0.09
Fair Value: C$0.83
Risk*: 4
Sector/Industry: Technology/Software
Q3 revenue was up 160% YoY, and 4% QoQ, beating our estimate by 3%.
Subscriber-count increased from 4k in September, to 5.1k currently; we are raising our year-end estimate from 5k to 5.25k.
Per our previous update in September, the company is in the process of shifting its marketing strategy by using more resellers and distributors, and in-house SEO marketing, instead of social media influencers. Management expects these initiatives to be more effective and cheaper. We are unable to comment on the effectiveness of these new initiatives until we see some preliminary results. For conservatism, we are lowering our near-term and long-term subscriber-count and revenue estimates.
Customer Acquisition Costs (CAC) remained well above $1,000 in Q3. Sekur expects to lower its CAC to $200-$250 in 2023, and to <$100 by 2024, vs subscription revenue of $150/year/user. We believe these cost reductions are achievable, if the company is able to ramp up its subscriber-base.
In 2023, the company is planning to launch new solutions/services, including VPN, encrypted calls, and video conferencing. These solutions can be bundled with existing solutions, or offered as stand-alone services.
2023 marketing will primarily target small businesses operating in the U.S. (approximately 32M. We continue to believe that businesses operating with sensitive and confidential information (such as medical, financial, and real estate) are ideal targets for Sekur.
Management is following through with their plan to up list shares to the NASDAQ; expected in 2023.
We expect tech stocks to be under pressure in the near-term, amid slower GDP growth, and as the Fed is expected to continue raising rates. That said, we are expecting the Fed to turn less hawkish by early next year, which should trigger a rally in tech stocks.
I have been right for the last 10 months on this.
I'll make a side bet to you and Bone (and Panzer) that this POS hits trips in 3 months.
Loving the lower volume rise and small stair steps. This is a great sign for the trend.
February 2023 Investor Deck
https://mindmed.co/wp-content/uploads/2023/02/MindMed-Investor-Presentation_Feb2023.pdf
Agreed mick
That is correct $P
New lows coming bone :)
Dead count bow bow bounce!
It's going to be a swell return in 2-3 years just have to hang tight. Swing on the way if you like.
100k outta do it ;)
People on Reddit are starting that mark is in talks with studios. If I could buy more I would. Things are going to heat up. Too much chatter and attention on this.
$MIKP very small company on an Expert Market. Which means you cannot buy in the US unless you have a broker that allows for it. It looks like this company (Mike the Pike Productions - $MIKP) obtained all rights to the Vampirella IP. Which is kind of big for the size of the company.
Wikipedia Entry -
https://en.wikipedia.org/wiki/Vampirella#Mike_The_Pike_Productions
On March 2, 2021, Mike The Pike Productions, Inc.'s subsidiary Arowana Media Holdings, Inc. acquired the worldwide film, television and streaming rights to Dynamite Entertainment's Vampirella. Including stories, characters, and derivative works of the Vampirella universe.
PR from a while ago supporting this.
https://finance.yahoo.com/news/mike-pike-productions-announces-arowana-120000077.html?guccounter=1&guce_referrer=aHR0cHM6Ly9lbi53aWtpcGVkaWEub3JnLw&guce_referrer_sig=AQAAADCxlZXvmvN9u3CM42waNF5fOAU9iSrly3fmDp9Y3DdBTV2dtdN8JV-Z6fcpMH_scS4dfEigGfWFlDUS91GClNi0F5SE3bYr2En4E-hSgaweNSZdE2X5f2yeLq8-rkP1UX1GRCka7tg3006khUiaSEumohRDJS919JGEU_xDPhaP
Chart is starting to wake up and a FORM 10 has been filed to become current and trading again soon. Have you seen this type of play before from this low of a value?
Wikipedia Entry -
https://en.wikipedia.org/wiki/Vampirella#Mike_The_Pike_Productions
On March 2, 2021, Mike The Pike Productions, Inc.'s subsidiary Arowana Media Holdings, Inc. acquired the worldwide film, television and streaming rights to Dynamite Entertainment's Vampirella. Including stories, characters, and derivative works of the Vampirella universe.
----
https://finance.yahoo.com/news/mike-pike-productions-announces-arowana-120000077.html?guccounter=1&guce_referrer=aHR0cHM6Ly9lbi53aWtpcGVkaWEub3JnLw&guce_referrer_sig=AQAAADCxlZXvmvN9u3CM42waNF5fOAU9iSrly3fmDp9Y3DdBTV2dtdN8JV-Z6fcpMH_scS4dfEigGfWFlDUS91GClNi0F5SE3bYr2En4E-hSgaweNSZdE2X5f2yeLq8-rkP1UX1GRCka7tg3006khUiaSEumohRDJS919JGEU_xDPhaP
Some chatter on this topic here I see: https://www.reddit.com/r/Vampirella/
Should be interesting soon.
Not sure why he'd own this type of IP without filing. I mean it's a pretty serious source of interest.
Because when this does take off it's going to take off fast!
Yeah I just did some more digging on it. This may go past .10 on hype. Huge crowd following Vampirella. Going to be one hell of a play. Curious to see how this plays out.
Chinese Spy Balloon will lift $SWISF
Chinese Spy Balloon should bring up this stock fast!
Chinese Spy Balloon should bring up this stock fast!
It really is a crazy IP to own for a company right now in the trips. I have some Vampirella comics that are signs by some of the artists.
Maybe we will see that .10 cents!
Wow. Wasn't even thinking that far ahead. That's would be insane. I'll be happy at a Nickle first! Buckle up!
Nice buys on Friday. Low volume but buys.
Wait for Trips!!!!
Interesting and agreeable theory
Exactly. Just stay the course. The board is on fire. Loving the attention. Come one come all!
New 52-week low! Boop!
Mick we will be good
Cardiovascular Systems (NASDAQ: CSII) Enters Into Agreement to be Acquired By Abbott Labs (NYSE: ABT) For $890 Million
by admin February 9, 2023
Cardiovascular Systems NASDAQ CSII Acquired By Abbott Labs NYSE ABT Spotlight Growth
Cardiovascular Systems NASDAQ CSII Acquired By Abbott Labs NYSE ABT Spotlight Growth
Cardiovascular Systems, Inc. (NASDAQ: CSII) is engaged as a medical device company, which is focused on the research, development and commercialization of novel solutions to treat coronary and vascular diseases. Shares of the heart medical device company are surging 48% through early trading on Thursday, February 9, 2023. Over the past three months, Cardiovascular Systems has seen average daily volume of 260,730 shares. However, volume of 5.16 million shares or dollar volume of around $101.7 million, has already exchanged hands through early trading.
Shares of Cardiovascular Systems are rallying after the company announced it has entered into a definitive agreement to be acquired by Abbott Labs (NYSE: ABT) for $20 per share or a total transaction value of $890 million. With the acquisition, Abbott Labs will leverage Cardiovascular Systems’ atherectomy platform, which prepares vessels for angioplasty or stenting. CSII’s platform will serve as a complementary solution to Abbott’s existing vascular disease assets.
Cardiovascular Systems is considered to be an industry leader with its atherectomy devices, which can treat plaque build-up in the arteries through a minimally invasive treatment process. Furthermore, the heart medical device company has an enticing pipeline of early-stage vascular intervention devices that would serve as a complement to its existing platform.
Abbott says the transaction is expected to have a neutral impact to the company’s recently issued 2023 guidance. The transaction still requires approval from Cardiovascular Systems shareholders and regulatory agencies.
“We are pleased to have reached an agreement with a leading global company that shares our passion for the development and commercialization of innovative solutions for treating complex peripheral vascular disease and coronary artery disease,” said Scott Ward, CSI’s chairman, president and chief executive officer. “We believe combining with Abbott delivers value to our patients, physician customers, employees and stockholders while continuing our work to save limbs and save lives every day.”
Right before the RS
It was all sells...
No way or I'll have a Bone to pick with you :)
Like the profile photo